Eletriptan Pharmacokinetics In Korean Males

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Eletriptan

Criteria

Inclusion Criteria:

• healthy male subjects, 18-55 years old

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

• provide informed consent

Exclusion Criteria:

• blood pressure >140/90 mm Hg

• any condition possibly affecting drug absorption

• positive urine drug screen